Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Martin J. Price"'
Challenges and proposed solutions to value assessment and reimbursement of CAR-T therapies in Europe
Autor:
Clare Hague, Martin J Price
Publikováno v:
Cell and Gene Therapy Insights. 6:1013-1028
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::46a3e83db15e8c8d66c28117608efa42
https://doi.org/10.18609/cgti.2020.111
https://doi.org/10.18609/cgti.2020.111
Reliability and validity of the Personal and Social Performance scale in patients with schizophrenia
Autor:
Douglas Turkington, Amory Clarke, Donald E. Stull, Katie Pascoe, Beenish Nafees, Patricia van Hanswijck de Jonge, Martin J. Price
Publikováno v:
Schizophrenia Research. 140:71-76
The construct validity and test-retest reliability of the Personal and Social Performance (PSP) scale were used to assess social functioning in a cohort of ethnically diverse UK patients with schizophrenia.A total of 73 patients with schizophrenia to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37c56f077448d5922c57bdf1549f5a61
https://doi.org/10.1016/j.schres.2012.06.013
https://doi.org/10.1016/j.schres.2012.06.013
Publikováno v:
The Psychiatrist. 35:95-100
Aims and methodRelapse in schizophrenia carries a heavy burden. This study aimed to describe the characteristics of patients admitted to hospital for relapse and to explore the treatment, length of stay and associated in-patient costs. The sample com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::797b43051441a5cca4b4f8ff2962bca1
https://doi.org/10.1192/pb.bp.109.027714
https://doi.org/10.1192/pb.bp.109.027714
Publikováno v:
PharmacoEconomics. 23:1167-1181
Introduction: Antiepileptic drugs (AEDs) have been shown to reduce the severity and frequency of seizures for most patients. However, many patients experience adverse effects in order to maintain seizure control. Study design: A stated preference dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf24399946f1ec3cecff1d28200cda08
https://doi.org/10.2165/00019053-200523110-00008
https://doi.org/10.2165/00019053-200523110-00008
Publikováno v:
Journal of Medical Economics. 7:29-40
SummaryA recent review found that economic assessment of epilepsy treatment relies largely on hypothetical modelling of outcomes and combining these with resource and cost data from different sources. Prospective evaluations combining cost studies wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::054c5f6fe31e4e8b884ca1cffc33842f
https://doi.org/10.3111/200407029040
https://doi.org/10.3111/200407029040
Publikováno v:
The European Journal of Health Economics. 4:271-278
Long-term comparative trials among newer antiepileptic drugs are lacking; therefore decision models are needed to guide treatment decisions. The goal of this study was to develop an economic model of newly diagnosed epilepsy in the UK and to provide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04295dfbfdd46fc36ee022904a7b09e8
https://doi.org/10.1007/s10198-003-0176-3
https://doi.org/10.1007/s10198-003-0176-3
Publikováno v:
American Journal of Respiratory Medicine. 1:435-440
Objective and design: Measurement of health-related quality of life (HR-QOL) may show benefits of asthma treatments not revealed by objective monitoring and can complement clinical and physiological assessments of treatment outcome. HR-QOL was measur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cf52cee253ada95fff90d990150aacb
https://doi.org/10.1007/bf03257170
https://doi.org/10.1007/bf03257170
Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma
Publikováno v:
Clinical Therapeutics. 22:1562-1574
Background: The results of a recent meta-analysis comparing 2 inhaled corticosteroids, fluticasone propionate (FP) and budesonide, demonstrated that FP had an improved efficacy-to-safety ratio compared with budesonide. However, limited data are avail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51e083cfed021c9a872d9b89967a398f
https://doi.org/10.1016/s0149-2918(00)83054-4
https://doi.org/10.1016/s0149-2918(00)83054-4
Autor:
Gunnar Johansson, Seema Sondhi, Robert M.A. Thwaites, Bo Lundbäck, Willem R. Pieters, Martin J. Price, Mona Palmqvist
Publikováno v:
PharmacoEconomics. 16:1-8
When a new drug therapy is introduced, it is important to consider the economic impact of the treatment. This is particularly relevant for a chronic disease such as asthma. Despite an increased understanding of the physiology of asthma, this conditio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::988eb0fc59c15c8b0b98f58755d1a488
https://doi.org/10.2165/00019053-199916002-00001
https://doi.org/10.2165/00019053-199916002-00001
Publikováno v:
PharmacoEconomics. 16:29-34
Methods: An economic analysis was performed to compare the cost effectiveness of a new formulation combining salmeterol 50μg and fluticasone propionate 500μg in a multidose dry powder (Diskus™) inhaler (n = 167) with that of fluticasone propionat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad3b7137807578b534f922e53367a708
https://doi.org/10.2165/00019053-199916002-00005
https://doi.org/10.2165/00019053-199916002-00005